Details for Patent: 8,546,399
✉ Email this page to a colleague
Which drugs does patent 8,546,399 protect, and when does it expire?
Patent 8,546,399 protects VENCLEXTA and is included in one NDA.
This patent has one hundred and forty patent family members in forty-three countries.
Summary for Patent: 8,546,399
| Title: | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
| Abstract: | Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. |
| Inventor(s): | Bruncko; Milan (Green Oaks, IL), Ding; Hong (Gurnee, IL), Doherty; George A. (Libertyville, IL), Elmore; Steven W. (Northbrook, IL), Hasvold; Lisa A. (Grayslake, IL), Hexamer; Laura (Grayslake, IL), Kunzer; Aaron R. (Schaumburg, IL), Song; Xiaohong (Grayslake, IL), Souers; Andrew J. (Evanston, IL), Sullivan; Gerard M. (Lake Villa, IL), Tao; Zhi-Fu (Gurnee, IL), Wang; Gary T. (Libertyville, IL), Wang; Le (Vernon Hills, IL), Wang; Xilu (Grayslake, IL), Wendt; Michael D. (Vernon Hills, IL), Mantei; Robert (Franklin, WI), Hansen; Todd M. (Grayslake, IL) |
| Assignee: | Abbvie Inc. (North Chicago, IL) |
| Application Number: | 12/787,682 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,546,399 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; |
Drugs Protected by US Patent 8,546,399
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-001 | Apr 11, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-002 | Apr 11, 2016 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,546,399
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2435432 | ⤷ Sign Up | PA2017015 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2435432 | ⤷ Sign Up | 300873 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2435432 | ⤷ Sign Up | 122017000031 | Germany | ⤷ Sign Up |
| European Patent Office | 2435432 | ⤷ Sign Up | CR 2017 00021 | Denmark | ⤷ Sign Up |
| European Patent Office | 2435432 | ⤷ Sign Up | C20170017 00231 | Estonia | ⤷ Sign Up |
| European Patent Office | 2435432 | ⤷ Sign Up | 1790021-8 | Sweden | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
